|
|
Profile
|
Delegates :
SAJI Hideo |
|
Incorporated :
June 25 , 2008 |
Paid in Capital :
100 Million yen |
Employees :
10 人 |
Address :
207 International Science Innovation Building East Wing Kyoto University 36-1 Yoshida-honmachi, Sakyo-ku, Kyoto KYOTO
〒6068501
|
TEL/FAX :
+81-75-754-0625 / +81-75-761-3577 |
URL：
http://www.ips-cell.net/e/ |
Attachment :
|
Mission/Background :
iPS Academia Japan, Inc. was established as an affiliate of Kyoto University in 2008 to promote the transfer of iPS cell-related technologies which was first generated by Professor Shinya Yamanaka’s group at Kyoto University, to industry for its commercialization. We license-in and license-out patents and patent applications relating to iPS cell technologies with a mission to share the fruit of iPS cell research for the good of all humanity. |
|
Technology & Business
|
As an TLO (Technology Licensing Organization), we have been granted sublicensing rights of patent and patent applications relating to iPS cell technologies from Kyoto Univ., and 14 other universities and research institutions in the world.
The number of patents and patent applications have licensed to us reached approximately 800 applications (approx. 200 families) as of August 2025. Those patents and patent applications are covering a wide variety of iPS cell technical field such as reprogramming technology including basic patents of Yamanaka factors, purification, differentiation, drug discovery, and so on.
We secure transparency of our license program by disclosing main financial conditions.
Concurrently with licensing-out activities, we are licensing-in various fields of patents or patent applications of for-profit and not-for-profit entities worldwide relates to the technologies of pluripotent stem cells including iPS cells.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
patents and patent applications relating to iPS cell technology
|
Others
|
Ex. the reprogramming patent for 4factors: Oct3/4, Klf4, c-Myc and Sox2, which was invented by Prof. Yamanaka at Kyoto Univ.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
[License-out] We have so far concluded license agreements with 317 entities: 135 domestics and 182 International, as of March 2026.
[License-in] The number of patents and patent applications have licensed to us reached approximately 800 applications (approx. 200 families) as of August 2025.
|
|
Alliance strategy
|
We are looking for the opportunities of license-in and license-out of patents and patent applications relating to a various technological field of pluripotent stem cells including iPS cells with the aim of technology transfer business.
|
|
|